(Press-News.org) Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical stage drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) recently approved the initial investigational new drug (IND) application for ISM3091 for the treatment of patients with solid tumors. This is Insilico's first oncology program to advance to the clinical validation stage.
The open-label, multicenter Phase I clinical trial of ISM3091 will be conducted simultaneously in the U.S. and China to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ISM3091 in patients with advanced solid tumors, and through dose escalation and dose optimization to identify the recommended dose level for Phase 2 monotherapy. Insilico has filed the IND submission to the U.S. FDA and the NMPA and expects to first initiate the study in the U.S. center in July 2023.
“We are developing and evaluating ISM3091, a potent and highly selective small molecule inhibitor of USP1, as a target anticancer agent,” said Sujata Rao, MD, SVP, Head of Global Clinical Development at Insilico Medicine. “PARP inhibitors (PARPi) are the first clinically approved drugs designed to exploit synthetic lethality, which have demonstrated positive clinical treatment effects. However, not all patients respond to PARPi, and those who do benefit often develop resistance. ISM3091 promises to be a next-generation synthetic lethal therapy with the potential to bring innovative solutions to patients with solid tumors.”
ISM3091 is a potentially best-in-class, orally available and highly selective small molecule inhibitor of USP1, which has emerged as a synthetic lethal target for cancer treatment that plays a crucial role in DNA damage response and repair. In preclinical experiments, ISM3091 was found to be potently efficacious against multiple tumor cell lines and in vivo models with BRCAm, as well as in HRR-proficient models. It is also well tolerated in different species with a high margin of safety. Insilico disclosed select data during a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in April 2023.
“ISM3091 is Insilico’s third internal program to advance to the clinical stage. We are pleased to see that it has demonstrated promising safety profiles and efficacy features in preclinical,” said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “The published patent of ISM3091 shows that the molecule designed with the support of Chemistry42 is distinctly novel, which once again shows the ability of AI to generate compounds from scratch. We are committed to taking advantage of AI-driven drug discovery to rapidly develop innovative therapeutics for unmet medical needs.”
The novel structure of ISM3091 was designed and optimized using Insilico's proprietary AI platform, Chemistry42, which is built on years of modeling and pre-training of large biological, chemical, and textual datasets and includes 42 generative engines and more than 500 predictive engines for scoring that allows researchers to generate molecules with desired properties through structure-based drug design (SBDD) and ligand-based drug design (LBDD). Relying on the synergy between its powerful AI platform and strong internal drug discovery expertise, Insilico nominated the preclinical candidate targeting USP1 in Apr 2022, only 9 months after the program was initiated.
“Since 2021, Insilico has nominated 12 preclinical candidate compounds, including ISM3091, the small molecule USP1 inhibitor, and our first oncology program to reach the clinical stage,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “We hope to further validate our candidate compound in the multicenter trial, as well as the capabilities of our AI-driven drug discovery platform.”
Powered by Pharma.AI, Insilico's proprietary drug discovery platform driven by generative AI, the company has developed an innovative portfolio comprising over 30 pipelines, with three leading programs in the clinical stage. Namely, ISM3091, a potential best-in-class USP1 inhibitor granted FDA IND approval; ISM3312, an orally available 3CLpro inhibitor with broad anti-coronavirus activity in Phase I trials; and ISM018_055, the first AI-discovered drug candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) already validated in Phase I and granted Orphan Drug Designation (ODD) by the FDA.
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
Website: www.insilico.com
END
Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
2023-05-25
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Quantum scientists accurately measure power levels one trillion times lower than usual
2023-05-25
Scientists in Finland have developed a nanodevice that can measure the absolute power of microwave radiation down to the femtowatt level at ultra-low temperatures – a scale trillion times lower than routinely used in verifiable power measurements. The device has the potential to significantly advance microwave measurements in quantum technology.
Measuring extremely low power
Quantum science takes place mostly at ultra-low temperatures using devices called dilution refrigerators. ...
Enhancing patient care by improving electronic health records: Plan outlines 3 'essential' steps
2023-05-25
An early advocate for the electronic health records now found in hospitals across the country has developed a plan to improve their use, lighten clinicians’ workload and enhance patient care.
The University of Virginia School of Medicine’s Don Detmer, MD, MA, designed the improvement plan in collaboration with Andrew Gettinger, MD, of Dartmouth’s Geisel School of Medicine. Detmer oversaw UVA’s adoption of electronic physician order entry in the early 1990s while vice president ...
Material design by means of defect engineering: German Research Foundation approves new Collaborative Research Center at Mainz University
2023-05-25
When we talk about defects, we generally think of flaws or impairments. However, as far as materials science is concerned, defects represent windows of opportunity. A new Collaborative Research Center (CRC) in the field of soft matter based at and administered by Johannes Gutenberg University Mainz (JGU) will explore these opportunities. The German Research Foundation (DFG) has approved CRC 1552 "Defects and Defect Engineering in Soft Matter" and will be providing funding of some EUR 8 million over the next four years. Also participating are the Max Planck Institute for Polymer Research and the Fraunhofer Institute for Microengineering and Microsystems ...
Scientists propose revolution in complex systems modelling with quantum technologies
2023-05-25
Scientists have made a significant advancement with quantum technologies that could transform complex systems modelling with an accurate and effective approach that requires significantly reduced memory.
Complex systems play a vital role in our daily lives, whether that be predicting traffic patterns, weather forecasts, or understanding financial markets. However, accurately predicting these behaviours and making informed decisions relies on storing and tracking vast information from events in the distant past – a process which presents huge challenges.
Current models using artificial intelligence see their ...
Certain cancers will likely rise exponentially due to COVID-19 screening delays
2023-05-25
Key Takeaways
Current cancer diagnoses compared with pre-pandemic rates: Researchers quantified missed diagnoses of lung, breast, and colorectal cancers by comparing observed cancer rates in 2020 with pre-pandemic cancer rates (2010-2019).
Potential increase in undiagnosed disease: Incidence rates for all three types of cancer have significantly decreased, suggesting that many patients may currently harbor undiagnosed disease.
Importance of screening: Study adds to the growing body of literature on pandemic-related disruptions and serves as a vital reminder to encourage all patients to stay up to date on their recommended cancer screenings.
CHICAGO: ...
UTHealth Houston awarded nearly $13M in grants to study treatments for traumatic brain injury
2023-05-25
Nearly $13 million in federal grant funds to study treatments for traumatic brain injury, which kills an average of 190 people and hospitalizes another 600 in the U.S. every day, has been awarded to UTHealth Houston by the Department of Defense’s Office of Congressionally Directed Medical Research Programs (CDMRP).
The funding marks a positive step forward for patients suffering from the medical condition, said Charles S. Cox Jr., MD, the George and Cynthia Mitchell Distinguished Chair in Neurosciences and the Glassell Family Distinguished Chair in the Department of Pediatric Surgery with McGovern ...
Research team receives grant to launch ‘Just Dis Tech’ project
2023-05-25
A group of Virginia Tech faculty who represent a variety of disciplines is bringing the principles of disability justice to Appalachia through educational workshops, cultural events, and technology research.
The team received a $502,000 grant from the Andrew Mellon Foundation to create local and regional programming for disability-led arts, culture, reflection, and technology guidance. The foundation is a nonprofit organization that funds arts and humanities work nationwide.
With the three-year project, called “Just ...
Weevils, long-nosed beetles, are unsung heroes of pollination
2023-05-25
Butterflies, bees, and even bats are celebrated as pollinators: creatures that travel from flower to flower to feed, and in the process, help fertilize the plants by spreading pollen. But some of nature’s most diverse pollinators often go unnoticed, even by scientists: long-snouted beetles called weevils. A new study in the journal Peer Community in Ecology provides a deep dive into the more than 600 species of weevils, including ones whose entire life cycles are interwoven with a specific plant that they help pollinate.
“Even people who work on pollination don't usually consider weevils as one of the main pollinators, and people who ...
An emergency department visit as part of a continuum of care
2023-05-25
INDIANAPOLIS -- Even before the COVID-19 pandemic, more than 100 million hospital emergency department (ED) visits took place annually in the U.S. In two studies, Regenstrief Institute Research Scientist Sharmistha Dev, M.D., MPH, and colleagues characterize an ED visit as part of a continuum of care, exploring how an ED visit is a valuable arena to support care beyond the issue that motivated the visit.
“Many people view a patient’s ED visit as a moment of acute care and a moment of dealing with just one issue and then the patient is either admitted or discharged. But ...
Social stress, problem-solving deficits contribute to suicide risk for teen girls
2023-05-25
Teen girls who have greater difficulty effectively solving interpersonal problems when they experience social stress, and who experience more interpersonal stress in their lives, are at greater risk of suicidal behavior, suggests research published by the American Psychological Association.
Suicide is the second-leading cause of death among teens, and rates of suicidal behavior are particularly high among girls. Previous research has found that interpersonal stressors – such as conflict with peers, friends and family – are related to suicidal behavior. Some theories of ...